Skip to content
Annuaire
Sections
Business

Sofinnova closes €725 million to fund Phase 3 trials in Europe

L’essentiel

Sofinnova Partners closes its Crossover II fund at €725 million for late-stage biotechs. What it changes for European healthcare.

À retenir

Sofinnova Partners closes its Crossover II fund at €725 million for late-stage biotechs. What it changes for European healthcare.

Paris-based asset manager Sofinnova Partners announced on 16 November the final close of its Crossover II fund at €725 million, or about $815 million. The vehicle targets around fifteen biotech and medical technology companies that have reached the most expensive stages of clinical development. It tackles a well-identified gap in European funding: Phase 3 trials, which seed funds cannot carry on their own.

A bigger fund than planned

According to Sofinnova’s press release, the final amount exceeds the initial target, a figure the firm did not disclose. The specialist site European Biotechnology calculates that Crossover II is 63% larger than its predecessor, closed at €445 million in March 2021 (Maddyness puts this first fund at around €500 million). Added to the €650 million Capital XI fund, closed in November 2025 for early stages, it brings the capital raised by the firm in one year to €1.375 billion.

Among the backers, only one is named: the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund. European Biotechnology also mentions sovereign wealth funds, insurers and public institutions, with many investors from the first fund coming back in, and a more international base than in 2021.

Phase 3, the weak link in funding

The strategy consists of taking stakes in companies, listed or not, that already have early clinical validation, and then helping them through the decisive clinical, regulatory and commercial stages. Kinam Hong, a partner at Sofinnova, sums up the challenge to Maddyness: “What is missing is funding for the last stage.” He puts the cost of a Phase 3 study at between €100 million and €300 million.

These amounts exceed what most European funds can commit to a single deal. The same partner explains to European Biotechnology that companies often need money for longer than announced, especially when stock markets remain closed to IPOs. Hence the choice of a concentrated portfolio, which keeps more capital for follow-on rounds.

Sofinnova, founded in 1972, is headquartered in Paris and has offices in London and Milan. According to Maddyness, it has been pursuing this so-called “crossover” strategy for nearly ten years. It plans to act as an active shareholder, with board seats.

What the first fund shows

Crossover I’s track record serves as a sales pitch. According to Maddyness, the sixteen companies in this first portfolio raised more than €3.4 billion, including Sofinnova’s contributions. Maddyness cites AstraZeneca’s acquisition of Amolyt Pharma in 2024 for about $1 billion, the purchase of LimFlow by US company Inari Medical for up to $415 million, and Asahi Kasei’s takeover of Calliditas Therapeutics. France’s Abivax, which joined the portfolio in 2019, is listed on Nasdaq and valued at more than $7.5 billion, according to the same outlet.

Three companies are already in the new fund: Denmark’s Hemab Therapeutics, a specialist in clotting disorders, Britain’s CellCentric, which specialises in oncology, and Ireland’s Neurent Medical, which focuses on chronic rhinitis. On 9 November, Hemab announced the launch of a pivotal Phase 3 trial in Glanzmann thrombasthenia, a rare bleeding disorder, according to a press release relayed by Sofinnova.

What it changes, and for whom

For French and European biotechs, the arrival of €725 million dedicated to late stages offers one more option besides an early sale to a US drugmaker or a stock market listing in a sluggish market. For seed funds, it also provides a relay: Kinam Hong argues to European Biotechnology that capital available at every stage benefits the whole ecosystem.

The limitation is well known. The same article points out that many smaller or newer managers are struggling to raise funds, which raises the question of money becoming concentrated among a few established players. With around fifteen planned holdings, Crossover II will fund only a handful of the European programmes seeking money for their Phase 3. And the origin of the non-European backers, which Sofinnova does not detail, has yet to be clarified.

Frequently asked questions

What is a “crossover” fund?

It is a fund that invests in late-stage companies, both before and after their stock market listing. It bridges traditional venture capital and public-market investors.

Why is Phase 3 so expensive?

It is the stage that tests a treatment on a large number of patients to prove its efficacy before approval. Sofinnova estimates its cost at between €100 million and €300 million per study.

Which companies have already received money from Crossover II?

Hemab Therapeutics (Denmark), CellCentric (United Kingdom) and Neurent Medical (Ireland). The fund plans around fifteen investments in total, mainly in Europe, with a few targeted stakes in the United States.

Sources

Sur votre appareil

Comprendre cet article

L’analyse utilise l’intelligence locale du navigateur lorsqu’elle existe, sinon un résumé extractif. Le texte n’est envoyé à aucun service extérieur.

Facebook X LinkedIn

Ensuite A lire aussi

Free, no spam, one-click unsubscribe.